Homobivalent ligands of the atypical antipsychotic clozapine: design, synthesis, and pharmacological evaluation.

Article Details

Citation

McRobb FM, Crosby IT, Yuriev E, Lane JR, Capuano B

Homobivalent ligands of the atypical antipsychotic clozapine: design, synthesis, and pharmacological evaluation.

J Med Chem. 2012 Feb 23;55(4):1622-34. doi: 10.1021/jm201420s. Epub 2012 Feb 2.

PubMed ID
22243698 [ View in PubMed
]
Abstract

To date all typical and atypical antipsychotics target the dopamine D(2) receptor. Clozapine represents the best-characterized atypical antipsychotic, although it displays only moderate (submicromolar) affinity for the dopamine D(2) receptor. Herein, we present the design, synthesis, and pharmacological evaluation of three series of homobivalent ligands of clozapine, differing in the length and nature of the spacer and the point of attachment to the pharmacophore. Attachment of the spacer at the N4' position of clozapine yielded a series of homobivalent ligands that displayed spacer-length-dependent gains in affinity and activity for the dopamine D(2) receptor. The 16 and 18 atom spacer bivalent ligands were the highlight compounds, displaying marked low nanomolar receptor binding affinity (1.41 and 1.35 nM, respectively) and functional activity (23 and 44 nM), which correspond to significant gains in affinity (75- and 79-fold) and activity (9- and 5-fold) relative to the original pharmacophore, clozapine. As such these ligands represent useful tools with which to investigate dopamine receptor dimerization and the atypical nature of clozapine.

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
ClozapineDopamine D2 receptorKi (nM)102.33N/AN/ADetails
ClozapineDopamine D2 receptorIC 50 (nM)204.17N/AN/ADetails
ClozapineDopamine D2 receptorKi (nM)106N/AN/ADetails
ClozapineDopamine D2 receptorIC 50 (nM)206N/AN/ADetails